These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 6977778

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Letter: Factor-VIII inhibitor bypassing activity.
    Pollock A, Lewis MJ.
    Lancet; 1976 Jul 03; 2(7975):43-4. PubMed ID: 59103
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Management of anterior compartment syndrome in two high responder factor VIII inhibitor patients with activated prothrombin complex concentrate.
    Christiansen SE, Ingerslev J, Wallevik K, Farsø F, Helmig O, Stenbjerg S.
    Thromb Res; 1986 Jun 01; 42(5):707-12. PubMed ID: 3487140
    [No Abstract] [Full Text] [Related]

  • 45. [Coagulation factors. Indications and applications].
    Stampfli K, Hartmann S.
    Ther Umsch; 1984 Aug 01; 41(8):571-5. PubMed ID: 6437000
    [No Abstract] [Full Text] [Related]

  • 46. Separation of an active substance responsible for the factor VIII inhibitor bypassing activity in Autoplex.
    Fukui H, Fujimura Y, Sugimoto M, Okubo Y, Yoshioka A.
    Nihon Ketsueki Gakkai Zasshi; 1985 Feb 01; 48(1):134-46. PubMed ID: 3873774
    [No Abstract] [Full Text] [Related]

  • 47. Characteristics and thrombogenicity of factor IX concentrate.
    Sakuragawa N, Takahashi K, Itoh M, Matsuoka M.
    Bibl Haematol; 1977 Feb 01; 44():88-93. PubMed ID: 617788
    [Abstract] [Full Text] [Related]

  • 48. Hemophilic dogs response to Bridge anticoagulant neutralizing agent.
    Nour-Eldin F.
    Transfusion; 1983 Feb 01; 23(6):533-4. PubMed ID: 6417849
    [Abstract] [Full Text] [Related]

  • 49. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
    Ullman M, Hoots WK.
    Haemophilia; 2006 Dec 01; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
    [Abstract] [Full Text] [Related]

  • 50. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma].
    Mischke R.
    Berl Munch Tierarztl Wochenschr; 1999 Dec 01; 112(10-11):394-9. PubMed ID: 10598358
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Hemophilia prophylaxis with factor VIII concentrate.
    Kasper CK, Dietrich SL, Rapaport SI.
    Arch Intern Med; 1970 Jun 01; 125(6):1004-9. PubMed ID: 4951928
    [No Abstract] [Full Text] [Related]

  • 53. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP, Reesink HW, Mannucci PM, Gringeri A, Ingerslev J, Brettler DB, Mauser-Bunschoten EP, Negrier C, Berntorp E, Smith OP, Shapiro AD.
    Vox Sang; 2000 Jun 01; 78(4):256-61. PubMed ID: 10970234
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Treatment of haemophilia.
    Ludlam CA.
    Br J Haematol; 1998 May 01; 101 Suppl 1():13-4. PubMed ID: 9607736
    [No Abstract] [Full Text] [Related]

  • 56. Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
    Kessler CM, Bernstein Z, Ghesani S, Shamsipour Z, Frances C, Zucker ML, LaDuca FM.
    Am J Hematol; 1996 Mar 01; 51(3):181-5. PubMed ID: 8619397
    [Abstract] [Full Text] [Related]

  • 57. [Reflections on the use of PPSB fraction (Prothrombin-proconvertin-Stuart factor-antihemophilic factor B)].
    Malinvaud G.
    Transfusion (Paris); 1966 Mar 01; 9(3):245-54. PubMed ID: 5969560
    [No Abstract] [Full Text] [Related]

  • 58. A haemophilia B patient with severe burn injury: increased requirement for factor IX replacement therapy associated with venous thromboembolism.
    Yaish H, Rodgers GM.
    Haemophilia; 2008 May 01; 14(3):607-9. PubMed ID: 18194306
    [No Abstract] [Full Text] [Related]

  • 59. The international factor IX treatment network survey.
    Berntorp E, Shapiro AD, Waters J, Astermark J, International Factor IX Treatment Network.
    Haemophilia; 2012 May 01; 18(3):e60-2. PubMed ID: 22404549
    [No Abstract] [Full Text] [Related]

  • 60. Preliminary characterization of a "factor VIII bypassing coagulant".
    Aronson DL, Bagley J.
    Ann N Y Acad Sci; 1981 May 01; 370():291-302. PubMed ID: 6791547
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.